Clinical research study| Volume 118, ISSUE 5, P515-520, May 2005

Download started.


Infliximab therapy in established rheumatoid arthritis: An observational study



      To investigate the efficacy, toxicity and drug discontinuation rate in an observational study of patients with established rheumatoid arthritis treated with infliximab.

      Subjects and methods

      Between September 1999 and June 2003, we enrolled 84 patients with rheumatoid arthritis who were being treated with infliximab. All patients met the American College of Rheumatology criteria for rheumatoid arthritis and had been refractory to (or did not tolerate) at least two disease-modifying antirheumatic drugs. Patients entering the study had a negative purified protein derivative skin test, were fully informed about the treatment regimen, and were followed up at predefined times according to a standardized protocol. Data concerning infliximab dosage, tolerability, adverse events, concomitant therapy, dosage interval, and drug discontinuation were all recorded. In addition, the clinical and laboratory variables according to the American College of Rheumatology 20% and 50% response criteria and the disease activity score for the 28 joint indices were also recorded.


      There were 61 women and 23 men with a mean age of 59 ± 8 years and mean disease duration of 11 ± 6 years. Seventy—five percent (63/84) were seropositive for IgM rheumatoid factor. After the first year of treatment, 84.5% of patients continued to be treated with infliximab, whereas this percentage was 73% after the second year and 59% after the third year of treatment. The American College of Rheumatology 20% response criteria was met by 59/84 (70%) of patients, and 38/84 (45%) of the patients achieved the 50% response criteria in the first year of treatment. At the second year of therapy, the American College of Rheumatology 20% response criteria were reached by 35/84 (42%) of the patients and the 50% response criteria by 27/84 (32%). At the third year of treatment with infliximab, the American College of Rheumatology 20% and 50% response criteria were achieved by 13/84 (15.5%) and 10/84 (12%) of the patients, respectively. Twenty-eight of eighty-four (33%) patients discontinued infliximab therapy. The risk of drug discontinuation decreased with the concomitant use of methotrexate. The main reasons for drug discontinuation were adverse drug reactions (16/84, 19%), followed by lack of efficacy (9/84, 11%). The main reasons for drug discontinuation due to side effects were immediate hypersensitivity reactions (9/84, 11%) and infections (6/84, 7%).


      Infliximab was found to be an alternative treatment with a relatively acceptable toxicity profile, despite the fact that two patients developed pulmonary tuberculosis. After the third year of therapy, 59% of patients continued to be treated with infliximab. The concomitant use of methotrexate was associated with the continuation of infliximab therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Harris Jr., E.D.
        Rheumatoid arthritis.
        N Engl J Med. 1990; 322: 1277-1289
        • Choy E.H.
        • Panayi G.S.
        Cytokine pathways and joint inflammation in rheumatoid arthritis.
        N Engl J Med. 2001; 344: 907-916
        • Drosos A.A.
        Newer immunosuppressive drugs.
        Drugs. 2002; 62: 891-907
        • Maini R.N.
        • Breedveld F.C.
        • Kalden J.R.
        • et al.
        Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
        Arthritis Rheum. 1998; 41: 1552-1563
        • Maini R.
        • St Clair E.W.
        • Breedveld F.
        • et al.
        • ATTRACT Study Group
        Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate.
        Lancet. 1999; 354: 1932-1939
        • Lipsky P.E.
        • van der Heijde D.M.
        • St Clair E.W.
        • et al.
        Infliximab and methotrexate in the treatment of rheumatoid arthritis.
        N Engl J Med. 2000; 343: 1594-1602
        • Arnett F.C.
        • Edworthy S.M.
        • Bloch D.A.
        • et al.
        The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
        Arthritis Rheum. 1988; 31: 315-324
        • Felson D.T.
        • Anderson J.J.
        • Boers M.
        • et al.
        American College of Rheumatology.
        Arthritis Rheum. 1995; 38: 727-735
        • Prevoo M.L.
        • van’t Hof M.A.
        • Kuper H.H.
        • et al.
        Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
        Arthritis Rheum. 1995; 38: 44-48
        • van de Putte L.B.
        • Krool E.J.
        • van Riel P.L.
        Management of refractory rheumatoid arthritis.
        Rheumatology (Oxford). 1999; 38: 32-34
        • Drosos A.A.
        Methotrexate intolerance in elderly patients with rheumatoid arthritis.
        Drugs Aging. 2003; 20: 723-736
        • Braun J.
        • Sieper J.
        • van der Heijde D.
        Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis.
        Ann Rheum Dis. 2003; 62: 1023-1024
        • Geborek P.
        • Crnkic M.
        • Petersson I.F.
        • Saxne T.
        • South Swedish Arthritis Treatment Group
        Etanercept, infliximab, and leflunomide in established rheumatoid arthritis.
        Ann Rheum Dis. 2002; 61: 793-798
        • Temekonidis T.I.
        • Georgiadis A.N.
        • Alamanos Y.
        • et al.
        Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis.
        Ann Rheum Dis. 2002; 61: 822-825
        • Ferraccioli G.F.
        • Assaloni R.
        • Di Poi E.
        • et al.
        Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate.
        Rheumatology. 2002; 41: 1109-1112
        • St Clair E.W.
        • Wagner C.L.
        • Fasanmade A.A.
        • et al.
        The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis.
        Arthritis Rheum. 2002; 46: 1451-1459
        • Schuerwegh A.J.
        • van Offel J.F.
        • Stevens W.J.
        • et al.
        Influence of therapy with chimeric monoclonal tumor necrosis factor α antibodies on intracellular cytokine profiles of T lemphocytes and monocytes in rheumatoid arthritis patients.
        Rheumatology. 2003; 42: 541-548
        • Kroesen S.
        • Widmer A.F.
        • Tyndall A.
        • Hasler P.
        Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF therapy.
        Rheumatology. 2003; 42: 617-621
        • Doran M.F.
        • Crowson C.S.
        • Pond G.R.
        • O’Fallon W.M.
        • Gabriel S.E.
        Frequency of infection in patients with rheumatoid arthritis compared with controls.
        Arthritis Rheum. 2002; 46: 2287-2293
        • Kindler V.
        • Sappino A.P.
        • Grau G.E.
        • Piguet P.F.
        • Vassalli P.
        The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.
        Cell. 1989; 56: 731-740
        • Mohan V.P.
        • Scanga C.A.
        • Yu K.
        • et al.
        Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis.
        Infect Immun. 2001; 69: 1847-1855
        • Keane J.
        • Gershon S.
        • Wise R.P.
        • et al.
        Tuberculosis associated with infliximab, a tumor necrosis factor alpha—neutralizing agent.
        N Engl J Med. 2001; 345: 1098-1104
        • De Rycke L.
        • Kruithof E.
        • Van Damme N.
        • et al.
        Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
        Arthritis Rheum. 2003; 48: 1015-1023